{"id":"https://openalex.org/W7225746663","doi":"https://doi.org/10.25251/0mwzx137","title":"Effects of Glucagon-Like Peptide-1 (GLP-1)\u2013Based Medications on Icotrokinra Efficacy, Safety, and Pharmacokinetics: Pooled Results Across ICONIC Phase 3 Studies","display_name":"Effects of Glucagon-Like Peptide-1 (GLP-1)\u2013Based Medications on Icotrokinra Efficacy, Safety, and Pharmacokinetics: Pooled Results Across ICONIC Phase 3 Studies","publication_year":2026,"publication_date":"2026-11-10","ids":{"openalex":"https://openalex.org/W7225746663","doi":"https://doi.org/10.25251/0mwzx137"},"language":"en","primary_location":{"id":"doi:10.25251/0mwzx137","doi":"https://doi.org/10.25251/0mwzx137","is_oa":true,"landing_page_url":"https://doi.org/10.25251/0mwzx137","pdf_url":null,"source":{"id":"https://openalex.org/S4210210594","display_name":"SKIN The Journal of Cutaneous Medicine","issn_l":"2574-1624","issn":["2574-1624"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","poland-20"],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"SKIN The Journal of Cutaneous Medicine","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","doaj"],"open_access":{"is_oa":true,"oa_status":"diamond","oa_url":"https://doi.org/10.25251/0mwzx137","any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5048521405","display_name":"Linda Stein Gold","orcid":"https://orcid.org/0000-0002-2758-1605","observed_orcids":["https://orcid.org/0000-0002-2758-1605"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Linda Stein Gold","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5128671901","display_name":"April Armstrong","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"April Armstrong","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5007797742","display_name":"Jennifer Soung","orcid":"https://orcid.org/0009-0009-5586-0677","observed_orcids":["https://orcid.org/0009-0009-5586-0677"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Jennifer Soung","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5000030131","display_name":"Ronald B. Vender","orcid":"https://orcid.org/0000-0002-2624-2724","observed_orcids":["https://orcid.org/0000-0002-2624-2724"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Ronald Vender","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5018416880","display_name":"Andrew Pink","orcid":"https://orcid.org/0000-0001-5151-5539","observed_orcids":["https://orcid.org/0000-0001-5151-5539"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Andrew Pink","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5023266127","display_name":"Lea Kephart","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Lea Kephart","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5005208048","display_name":"Bassey Effiom Edem","orcid":"https://orcid.org/0000-0002-9783-1542","observed_orcids":["https://orcid.org/0000-0002-9783-1542"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Bassey Effiom Edem","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5159017129","display_name":"Ofelia Reyes-Servin","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Ofelia Reyes-Servin","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5161412428","display_name":"Shu Li","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Shu Li","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5100593065","display_name":"Ya-Wen Yang","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Ya-Wen Yang","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5148482548","display_name":"Christopher Russo","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Christopher Russo","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5040803542","display_name":"Benjamin Ungar","orcid":"https://orcid.org/0000-0003-0882-8163","observed_orcids":["https://orcid.org/0000-0003-0882-8163"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Benjamin Ungar","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5038505651","display_name":"Mark Lebwohl","orcid":"https://orcid.org/0000-0002-4705-5303","observed_orcids":["https://orcid.org/0000-0002-4705-5303"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Mark Lebwohl","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":0.0,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":{"value":0.0,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":"10","issue":"6","first_page":"s838","last_page":"s838"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10469","display_name":"Psoriasis: Treatment and Pathogenesis","score":0.9965999722480774,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10469","display_name":"Psoriasis: Treatment and Pathogenesis","score":0.9965999722480774,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10837","display_name":"Dermatology and Skin Diseases","score":0.0006000000284984708,"subfield":{"id":"https://openalex.org/subfields/2708","display_name":"Dermatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12433","display_name":"Skin Diseases and Diabetes","score":0.0003000000142492354,"subfield":{"id":"https://openalex.org/subfields/2708","display_name":"Dermatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8299999833106995},{"id":"https://openalex.org/C2779384505","wikidata":"https://www.wikidata.org/wiki/Q17007513","display_name":"Concomitant","level":2,"score":0.6588000059127808},{"id":"https://openalex.org/C2780564577","wikidata":"https://www.wikidata.org/wiki/Q179945","display_name":"Psoriasis","level":2,"score":0.6092000007629395},{"id":"https://openalex.org/C27081682","wikidata":"https://www.wikidata.org/wiki/Q269829","display_name":"Placebo","level":3,"score":0.5877000093460083},{"id":"https://openalex.org/C2779159551","wikidata":"https://www.wikidata.org/wiki/Q1414874","display_name":"Comorbidity","level":2,"score":0.5841000080108643},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.4880000054836273},{"id":"https://openalex.org/C2908647359","wikidata":"https://www.wikidata.org/wiki/Q2625603","display_name":"Population","level":2,"score":0.48420000076293945},{"id":"https://openalex.org/C112705442","wikidata":"https://www.wikidata.org/wiki/Q323936","display_name":"Pharmacokinetics","level":2,"score":0.4657999873161316},{"id":"https://openalex.org/C2777288759","wikidata":"https://www.wikidata.org/wiki/Q4164182","display_name":"Dosing","level":2,"score":0.415800005197525},{"id":"https://openalex.org/C3017906399","wikidata":"https://www.wikidata.org/wiki/Q48973845","display_name":"Pooled analysis","level":3,"score":0.4036000072956085},{"id":"https://openalex.org/C2780221984","wikidata":"https://www.wikidata.org/wiki/Q131191","display_name":"Body mass index","level":2,"score":0.3700999915599823},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.3650999963283539},{"id":"https://openalex.org/C168563851","wikidata":"https://www.wikidata.org/wiki/Q1436668","display_name":"Randomized controlled trial","level":2,"score":0.36390000581741333},{"id":"https://openalex.org/C3018359032","wikidata":"https://www.wikidata.org/wiki/Q1550789","display_name":"Safety profile","level":3,"score":0.3562000095844269},{"id":"https://openalex.org/C511355011","wikidata":"https://www.wikidata.org/wiki/Q12174","display_name":"Obesity","level":2,"score":0.3560999929904938},{"id":"https://openalex.org/C2777011040","wikidata":"https://www.wikidata.org/wiki/Q390643","display_name":"Psoriasis Area and Severity Index","level":3,"score":0.33090001344680786},{"id":"https://openalex.org/C555293320","wikidata":"https://www.wikidata.org/wiki/Q12206","display_name":"Diabetes mellitus","level":2,"score":0.3228999972343445},{"id":"https://openalex.org/C1862650","wikidata":"https://www.wikidata.org/wiki/Q186005","display_name":"Physical therapy","level":1,"score":0.29910001158714294},{"id":"https://openalex.org/C31760486","wikidata":"https://www.wikidata.org/wiki/Q7180990","display_name":"Phases of clinical research","level":3,"score":0.2976999878883362},{"id":"https://openalex.org/C2780586474","wikidata":"https://www.wikidata.org/wiki/Q332428","display_name":"Overweight","level":3,"score":0.2912999987602234},{"id":"https://openalex.org/C30036603","wikidata":"https://www.wikidata.org/wiki/Q17125150","display_name":"Severity of illness","level":2,"score":0.27950000762939453},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.2777000069618225},{"id":"https://openalex.org/C2777683783","wikidata":"https://www.wikidata.org/wiki/Q221174","display_name":"Topiramate","level":3,"score":0.2694000005722046},{"id":"https://openalex.org/C151956035","wikidata":"https://www.wikidata.org/wiki/Q1132755","display_name":"Logistic regression","level":2,"score":0.26809999346733093},{"id":"https://openalex.org/C61470247","wikidata":"https://www.wikidata.org/wiki/Q7229825","display_name":"Population study","level":3,"score":0.26489999890327454},{"id":"https://openalex.org/C2778715236","wikidata":"https://www.wikidata.org/wiki/Q55622662","display_name":"Discontinuation","level":2,"score":0.2578999996185303},{"id":"https://openalex.org/C205545832","wikidata":"https://www.wikidata.org/wiki/Q17156455","display_name":"Young adult","level":2,"score":0.2533999979496002}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.25251/0mwzx137","doi":"https://doi.org/10.25251/0mwzx137","is_oa":true,"landing_page_url":"https://doi.org/10.25251/0mwzx137","pdf_url":null,"source":{"id":"https://openalex.org/S4210210594","display_name":"SKIN The Journal of Cutaneous Medicine","issn_l":"2574-1624","issn":["2574-1624"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","poland-20"],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"SKIN The Journal of Cutaneous Medicine","raw_type":"journal-article"}],"best_oa_location":{"id":"doi:10.25251/0mwzx137","doi":"https://doi.org/10.25251/0mwzx137","is_oa":true,"landing_page_url":"https://doi.org/10.25251/0mwzx137","pdf_url":null,"source":{"id":"https://openalex.org/S4210210594","display_name":"SKIN The Journal of Cutaneous Medicine","issn_l":"2574-1624","issn":["2574-1624"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","poland-20"],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"SKIN The Journal of Cutaneous Medicine","raw_type":"journal-article"},"sustainable_development_goals":[],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":2,"referenced_works":["https://openalex.org/W4415937993","https://openalex.org/W4415992105"],"related_works":[],"abstract_inverted_index":{"Introduction:":[0],"In":[1,185,354],"pivotal":[2],"Phase":[3],"3":[4],"studies,":[5,300],"icotrokinra":[6],"(ICO)":[7],"has":[8],"demonstrated":[9],"significant":[10],"skin":[11],"clearance":[12],"with":[13,20,38,48,76,104,330,335,345],"a":[14,35,86],"favorable":[15],"safety":[16],"profile":[17],"in":[18,52,64,132,247,310,317,322,343,380],"patients":[19],"moderate-to-severe":[21],"psoriasis":[22,27,39],"(ICONIC-LEAD,":[23],"ICONIC-ADVANCE":[24,135],"1&2)":[25],"and":[26,40,62,111,134,175,202,240,274,314,332,347,362,382,387],"affecting":[28],"high-impact":[29],"sites":[30],"(ICONIC-TOTAL).":[31],"Because":[32],"obesity":[33],"is":[34,44,373],"common":[36],"comorbidity":[37],"GLP-1":[41,79,199,211,224,236,257,295,350,369,385,390],"medication":[42,80,351,370,391],"use":[43,47,81],"increasing,":[45],"concomitant":[46],"ICO":[49,59,123,170,179,312,331,338,359],"may":[50],"occur":[51],"clinical":[53],"practice.":[54],"These":[55],"post-hoc":[56,357],"analyses":[57],"evaluated":[58,147],"efficacy,":[60,360],"safety,":[61,361],"pharmacokinetics":[63,363],"ICONIC":[65],"study":[66,91],"participants":[67,75,119,159,208,222,234,249,292,344],"who":[68,165,250],"received":[69],"GLP-1\u2013based":[70],"medications.":[71],"Methods:":[72],"Data":[73],"from":[74,107,167,176],"versus":[77],"without":[78,348],"(defined":[82],"as":[83],"receipt":[84],"of":[85,368,384,389],"first":[87],"dose":[88],"prior":[89,226],"to":[90,121,141,161,169,178,198,210,227,256,294],"Day":[92],"84)":[93],"were":[94,155,192,251,262,278,303,327,341,364],"pooled":[95,187,325,356],"across":[96,148,297],"studies.":[97],"Efficacy":[98],"(Investigator\u2019s":[99],"Global":[100],"Assessment":[101],"[IGA]":[102],"0/1":[103,260],"\u22652-grade":[105],"improvement":[106],"baseline;":[108],"Psoriasis":[109],"Area":[110],"Severity":[112],"Index":[113],"[PASI]":[114],"90)":[115],"was":[116,138,146],"assessed":[117,156],"for":[118,157,307],"randomized":[120],"once-daily":[122],"200":[124],"mg":[125],"or":[126],"placebo":[127],"(PBO)":[128],"through":[129,152,305],"Week":[130],"(W)16":[131],"ICONIC-LEAD":[133],"1&2":[136],"(ICONIC-TOTAL":[137],"excluded":[139],"due":[140],"different":[142],"enrollment":[143],"criteria/endpoints).":[144],"Safety":[145],"all":[149,158,298],"4":[150,299],"studies":[151],"W16.":[153],"Pharmacokinetics":[154],"exposed":[160,197,209,252,255,293],"ICO,":[162],"including":[163],"those":[164,196],"switched":[166],"PBO":[168,319],"at":[171,180],"W16":[172,246,306],"(all":[173],"studies)":[174],"deucravacitinib":[177],"W24":[181],"(ICONIC-ADVANCE":[182],"1&2).":[183],"Results:":[184],"the":[186,203,311,318,323],"efficacy":[188],"population,":[189],"baseline":[190],"characteristics":[191],"generally":[193,365],"similar":[194,342],"between":[195,238],"mediations":[200],"(n=31)":[201],"total":[204],"population":[205,326],"(n=2187),":[206],"except":[207],"medications":[212,296],"had":[213],"higher":[214],"mean":[215],"BMI":[216],"(41.6":[217],"vs":[218,253,265,271,281,287],"29.5":[219],"kg/m2).":[220],"Most":[221],"started":[223,235],"therapy":[225,237],"W0":[228,239],"(n=24;":[229],"range,":[230],"10-1589":[231],"days);":[232],"7":[233],"W12":[241],"(range,":[242],"1-75":[243],"days).":[244],"At":[245],"ICO-treated":[248],"not":[254],"medications,":[258],"IGA":[259],"responses":[261,277],"65.0%":[263],"(13/20)":[264],"67.5%":[266],"(722/1069)":[267],"(PBO,":[268,284],"18.2%":[269],"[2/11]":[270],"9.0%":[272],"[41/455]),":[273],"PASI":[275],"90":[276],"45.0%":[279],"(9/20)":[280],"53.5%":[282],"(572/1069)":[283],"9.1%":[285],"[1/11]":[286],"3.5%":[288],"[16/455]),":[289],"respectively.":[290],"Among":[291],"adverse":[301],"events":[302],"reported":[304],"53.3%":[308],"(16/30)":[309],"group":[313,320],"69.2%":[315],"(9/13)":[316],"(rates":[321],"overall":[324],"49.1%":[328],"[636/1296]":[329],"51.9%":[333],"[295/568]":[334],"PBO).":[336],"Pharmacokinetic":[337],"exposures":[339],"(AUC)":[340],"(n=76)":[346],"(n=2291)":[349],"use.":[352,371],"Conclusion:":[353],"these":[355],"analyses,":[358],"consistent":[366],"regardless":[367],"Interpretation":[372],"limited":[374],"by":[375,395],"small":[376],"sample":[377],"sizes,":[378],"heterogeneity":[379],"timing":[381],"duration":[383],"exposure,":[386],"lack":[388],"dosing":[392],"details.":[393],"Supported":[394],"Johnson":[396],"&":[397],"Johnson.":[398]},"counts_by_year":[],"updated_date":"2026-11-11T12:16:26.678958","created_date":"2026-11-11T00:00:00"}